Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHILLES study of afatinib versus platinum-pemetrexed chemotherapy in EGFR uncommon mutation-positive advanced non-small cell lung cancer
jRCTs031180175Phase 3Completed
- Sponsor
- Japan Thoracic Oncology Research Group
- Start
- Apr 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of afatinib, cisplatin, carboplatin and pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Japan Thoracic Oncology Research Group. Primary endpoint: Progression-free survival. Started Apr 2019; status: completed.
02
Drugs
afatinibcisplatincarboplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031180175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180175.